Nifekalant
Alternative Names: MS 551; ShinbitLatest Information Update: 21 Mar 2011
At a glance
- Originator Nihon Schering
- Developer Bayer Yakuhin
- Class Class III antiarrhythmics; Pyrimidinones; Small molecules
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Arrhythmias
Most Recent Events
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
- 28 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Arrhythmias therapeutic trials section
- 25 May 2005 A study has been added to the adverse events and Arrhythmias therapeutic trials sections